PTPRC and neoplasm: The inhibition of CCL2 in MSC by CRISPR-Cas9 Knock out enhances MSC anti-tumor activity, with an increase in pro-inflammatory CD45+CD11b+ mononuclear myeloid cells in tumors [148].